drug
Wegovy Pill
Marketedupdated 3mo agoby Novo Nordisk Inc
Approvedannual revenue · 2024–2024peak $8.4B
community read0 votes
🐶 often sniffed alongside
top 8- drugOzempic168 co-mentions · 74 sources
- drugWegovy168 co-mentions · 74 sources
- tagApproval124 co-mentions · 44 sources
- drugRybelsus94 co-mentions · 72 sources
- drugsemaglutide94 co-mentions · 72 sources
- tagRecall33 co-mentions · 27 sources
- companyNovo Nordisk Inc22 co-mentions · 3 sources
- tagSmall Molecule22 co-mentions · 18 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 30 investigational indications.
indications
investigational
Obesity
all catalysts(2)
Trials studying Wegovy Pill
- phase3A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- phase3A Study of BGM0504 in Early T2DM With Obesity
- phase2Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
- phase3A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- phase4Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
- phase1Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 8, 2027
208 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (165)
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- Feb 17, 2041formulationUS 11318191
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- May 13, 2040method-of-use (U-3861)US 11478533
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 11833248
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Feb 1, 2039formulationUS 12396953
- Oct 10, 2038method-of-use (U-4418)US 12029779
- Oct 10, 2038method-of-use (U-3162)US 12029779
- Oct 10, 2038method-of-use (U-2628)US 12295988
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Oct 10, 2038method-of-use (U-4418)US 12551536
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 10888605
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 11752198
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Aug 24, 2038formulationUS 12214017
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4443)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- Apr 28, 2037method-of-use (U-4446)US 12569543
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-4389)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034method-of-use (U-2628)US 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034compositionUS 10278923
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034compositionUS 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-4388)US 12239739
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- May 2, 2034method-of-use (U-2628)US 12514822
- Jun 21, 2033formulationUS 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-2580)US 10335462
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Jun 21, 2033method-of-use (U-4418)US 9764003
- Jun 21, 2033method-of-use (U-3161)US 9764003
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 10933120
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759501
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759502
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Mar 15, 2033formulationUS 11759503
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10086047
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031formulationUS 10960052
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031compositionUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 11382957
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031compositionUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 16, 2031formulationUS 9278123
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Dec 5, 2031compositionUS 8129343
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
- Mar 20, 2026compositionUS 8536122
FDA exclusivities (29)
- Dec 22, 2028NPNP2.4y
- Dec 22, 2028NPNP2.4y
- Dec 22, 2028NPNP2.4y
- Dec 22, 2028NPNP2.4y
- Oct 17, 2028I-976Indication (3y)2.2y
- Oct 17, 2028I-976Indication (3y)2.2y
- Oct 17, 2028I-976Indication (3y)2.2y
- Oct 17, 2028I-976Indication (3y)2.2y
- Oct 17, 2028I-976Indication (3y)2.2y
- Oct 17, 2028I-976Indication (3y)2.2y
- Aug 15, 2028I-973Indication (3y)2.0y
- Aug 15, 2028I-973Indication (3y)2.0y
- Aug 15, 2028I-973Indication (3y)2.0y
- Aug 15, 2028I-973Indication (3y)2.0y
- Aug 15, 2028I-973Indication (3y)2.0y
- Jan 28, 2028I-961Indication (3y)1.5y
- Jan 28, 2028I-961Indication (3y)1.5y
- Jan 28, 2028I-961Indication (3y)1.5y
- Jan 28, 2028I-961Indication (3y)1.5y
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Mar 8, 2027I-935Indication (3y)208d
- Jul 21, 2026D-190New Indication (3y)
News(10)
- Scholar Rock rejigs approval filing after FDA flags violations at Novo plantDespite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.biospace · 21h ago
- Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugsMedicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.stat · 1d ago
- Novo Nordisk’s CFO on the oral Wegovy rollout and beyondNovo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.fiercebiotech · 5d ago
- Actimed gets back rights to wasting disease drug, ending $126M deal with FaradayActimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.fiercebiotech · 6d ago
- Lilly confident in slow and steady Foundayo launch, as ex-US sales shineFoundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.biospace · 6d ago
- Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsA legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…biospace · 6d ago
- Lilly climbs, Novo falls as obesity drug battle intensifiesA research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.biopharma_dive · 6d ago
- Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the e…biospace · 6d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 6d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 7d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that